Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke

Completed · Phase 3

Conditions studied: Stroke, Acute, Blood Pressure, Mechanical Thrombectomy

In brief

The CLEVER Study is a prospective, 2-arm, randomized, single-center pilot study to assess the safety and efficacy of intensive blood pressure control using Clevidipine (on-label use) in AIS patients undergoing standard of care mechanical thrombectomy (MT) within 24-hours of symptoms onset.

Key facts

Study ID: NCT05175547
Run by: ProMedica Health System
People needed: 80
Starts: 2021-10-30
Expected to finish: 2024-02-28
Last updated by the study team: 2025-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

1. Age 18 or older
2. Acute hypertension (systolic blood pressure of greater than 140 mmHg) at recanalization
3. Anterior circulation ischemic stroke symptoms and confirmed occlusion (ICA, M1, or M2) on angiogram with mechanical thrombectomy initiated within 24 hours since last known well
4. Success revascularization score of mTICI 2c or higher after mechanical thrombectomy
5. ASPECTS score of greater than 6
6. Premorbid mRS 0-4
7. Signed informed consent within 30 minutes from end of MT procedure.

You may not qualify if…

1. Presence of any hemorrhage and/or ASPECT score ≤6 on baseline head CT scan
2. Pregnant or lactating
3. Acute traumatic brain injury
4. Patient on active dialysis
5. Intracranial neoplasm
6. Acute or recent STEMI in the last 30 days
7. Severe arrhythmias, unstable cardiac function
8. Any terminal medical condition with life expectancy less than 6 months
9. Concurrent enrollment in another trial that could confound the results of this study

Where it is running

ProMedica Toledo Hospital — Toledo, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.